PetMed Express, Inc. (PETS)
NASDAQ: PETS · Real-Time Price · USD
2.601
-0.009 (-0.34%)
Mar 9, 2026, 12:56 PM EDT - Market open
PetMed Express Revenue
PetMed Express had revenue of $40.66M in the quarter ending December 31, 2025, a decrease of -21.75%. This brings the company's revenue in the last twelve months to $186.96M, down -20.69% year-over-year. In the fiscal year ending March 31, 2025, PetMed Express had annual revenue of $226.97M, down -17.19%.
Revenue (ttm)
$186.96M
Revenue Growth
-20.69%
P/S Ratio
0.30
Revenue / Employee
$1,080,717
Employees
173
Market Cap
55.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 226.97M | -47.12M | -17.19% |
| Mar 31, 2024 | 274.10M | 26.53M | 10.71% |
| Mar 31, 2023 | 247.57M | -24.71M | -9.08% |
| Mar 31, 2022 | 272.28M | -31.30M | -10.31% |
| Mar 31, 2021 | 303.58M | 19.46M | 6.85% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Eli Lilly and Company | 65.18B |
| AbbVie | 61.16B |
| Novartis AG | 56.67B |
| electroCore | 29.84M |
| Metagenomi Therapeutics | 25.21M |
PETS News
- 2 months ago - Cardone Ventures Announces Unsolicited $4.25 Per Share All-Cash Proposal to Acquire PetMed Express - Business Wire
- 3 months ago - PetMed Express Comments on Unsolicited and Non-Binding Acquisition Proposal Received From SilverCape Investments Limited - GlobeNewsWire
- 3 months ago - PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them - GlobeNewsWire
- 3 months ago - PetMeds Extends Existing Shareholder Rights Plan - GlobeNewsWire
- 3 months ago - Pets At Home's Shares Purr As Retailer Avoids Fresh Profit Warning - Forbes
- 4 months ago - PetMed Express, Inc. Announces Preliminary Second Quarter Results and Filing of Form 12b-25; Company Receives Expected Notice of Non-Compliance from Nasdaq - GlobeNewsWire
- 4 months ago - PETMED EXPRESS INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds PetMed Express Investors of the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 5 months ago - PetMed Express, Inc. Appoints Former Deloitte Partner James LaCamp as Director and Audit Committee Chair - GlobeNewsWire